Drug Trial Radar · NCT03772041
Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure
Last checked: Nov 20, 2026Latest source record: Aug 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
294
Actual
Start
Jan 16, 2019
Primary completion
Jul 21, 2020
Study completion Jul 29, 2020
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Co., Ltd.Otsuka
- Sponsor type
- Industry
- First posted
- Dec 11, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To confirm the non-inferiority of OPC-61815 16-mg injection to tolvaptan 15-mg tablet using as the primary endpoint the change in body weight following 5-day intravenous administration of OPC-61815 16-mg injection or 5-day oral administration of tolvaptan 15-mg tablet to CHF patients with volume overload despite having received diuretics other than vasopressin antagonists
Conditions
- Congestive Heart Failure
Interventions
OPC-61815Drug
Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg
Tolvaptan Tab 15 MGDrug
Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Body WeightTime frame: Baseline, Day 6
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Saiseikai Kumamoto Hospital
Kumamoto, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.